|
|
|
|
|
My Recent Searches
|
|
|
|
|
|
|
Avalo Therapeutics, Inc (AVTX) |
|
|
$0.43 0.00 (0.00%) as of 4:30 Thu 7/7
|
|
Download |
|
|
|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
112,320,000 |
Market
Cap: |
48.31(M) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$0.4301 - $0.4301 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Avalo Therapeutics is a clinical-stage precision medicine company that discovers, develops, and commercializes targeted therapeutics for patients with unmet clinical need in immunology and rare genetic diseases. Co.'s clinical-stage pipeline include: AVTX-002, which is developing for the treatment of non-eosinophilic asthma, inflammatory bowel disease; AVTX-007, which is developing AVTX-007 for the treatment of Still's Disease; AVTX-801, which is a D-galactose substrate replacement therapy for the treatment of phosphoglucomutase 1 deficiency; and AVTX-803, which is a L-fucose substrate replacement therapy for the treatment of LADII.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
79,351 |
662,763 |
Total Buy Value |
$0 |
$0 |
$272,578 |
$643,635 |
Total People Bought |
0 |
0 |
3 |
4 |
Total Buy Transactions |
0 |
0 |
18 |
32 |
Total Shares Sold |
0 |
0 |
5,291,542 |
5,291,542 |
Total Sell Value |
$0 |
$0 |
$3,199,077 |
$3,199,077 |
Total People Sold |
0 |
0 |
2 |
2 |
Total Sell Transactions |
0 |
0 |
4 |
4 |
End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Boyd Steven |
Director |
|
2020-01-24 |
4 |
A |
$0.00 |
$0 |
D/D |
3,000,000 |
28,683,233 |
|
- |
|
Boyd Steven |
Director |
|
2020-01-22 |
4 |
A |
$0.00 |
$0 |
D/D |
5,000,000 |
25,683,233 |
|
- |
|
Miller Joseph M |
Chief Financial Officer |
|
2019-12-10 |
4 |
B |
$2.85 |
$7,398 |
D/D |
2,598 |
48,777 |
2.74 |
- |
|
Harrell James Archie Jr |
Chief Commercial Officer |
|
2019-12-10 |
4 |
B |
$2.85 |
$8,725 |
D/D |
3,064 |
11,618 |
2.74 |
- |
|
Calias Pericles |
Chief Scientific Officer |
|
2019-12-10 |
4 |
B |
$2.85 |
$8,295 |
D/D |
2,913 |
52,462 |
2.74 |
- |
|
Boyd Steven |
Director |
|
2019-09-06 |
4 |
B |
$0.00 |
$0 |
I/I |
0 |
20,683,233 |
2.17 |
- |
|
Boyd Steven |
Director |
|
2019-09-06 |
4 |
B |
$2.95 |
$2,950,000 |
D/D |
1,000,000 |
20,683,233 |
3.92 |
- |
|
Boyd Steven |
Director |
|
2019-09-04 |
4 |
B |
$3.13 |
$3,756,000 |
D/D |
1,200,000 |
19,683,233 |
3.92 |
- |
|
Boyd Steven |
Director |
|
2019-08-30 |
4 |
B |
$3.23 |
$79,429 |
D/D |
24,591 |
18,483,233 |
3.92 |
- |
|
Boyd Steven |
Director |
|
2019-08-29 |
4 |
B |
$3.21 |
$55,125 |
D/D |
17,173 |
18,458,642 |
3.92 |
- |
|
Pedder Simon |
Executive Chairman of the Bd |
|
2019-08-27 |
4 |
B |
$2.98 |
$20,100 |
D/D |
6,734 |
262,734 |
2.81 |
- |
|
Phillips Matthew V |
Chief Commercial Officer |
|
2019-08-23 |
4 |
A |
$1.07 |
$548,375 |
I/I |
512,500 |
512,500 |
|
- |
|
Boyd Steven |
Director |
|
2019-08-19 |
4 |
B |
$0.00 |
$0 |
I/I |
0 |
18,441,469 |
2.17 |
- |
|
Boyd Steven |
Director |
|
2019-08-19 |
4 |
B |
$3.50 |
$8,280 |
D/D |
2,298 |
18,441,469 |
3.84 |
- |
|
Boyd Steven |
Director |
|
2019-08-16 |
4 |
B |
$0.00 |
$0 |
I/I |
0 |
18,439,171 |
2.17 |
- |
|
Boyd Steven |
Director |
|
2019-08-16 |
4 |
B |
$3.43 |
$33,909 |
D/D |
9,886 |
18,439,171 |
3.92 |
- |
|
Boyd Steven |
Director |
|
2019-08-14 |
4 |
B |
$3.37 |
$191,558 |
D/D |
56,842 |
400,000 |
3.92 |
- |
|
Boyd Steven |
Director |
|
2019-08-13 |
4 |
B |
$3.30 |
$96,320 |
I/I |
29,188 |
343,158 |
2.25 |
- |
|
Boyd Steven |
Director |
|
2019-08-12 |
4 |
B |
$3.20 |
$44,704 |
I/I |
13,970 |
313,970 |
2.25 |
- |
|
Calias Pericles |
Chief Scientific Officer |
|
2019-07-16 |
4 |
D |
$4.90 |
$15,905 |
D/D |
(3,246) |
49,216 |
|
- |
|
Phillips Matthew V |
Chief Commercial Officer |
|
2019-06-10 |
4 |
B |
$2.85 |
$1,489 |
D/D |
523 |
1,020 |
2.66 |
- |
|
Miller Joseph M |
Chief Financial Officer |
|
2019-06-10 |
4 |
B |
$2.85 |
$3,357 |
D/D |
1,179 |
46,179 |
2.66 |
- |
|
Calias Pericles |
Chief Scientific Officer |
|
2019-06-10 |
4 |
B |
$2.85 |
$12,953 |
D/D |
4,549 |
49,549 |
2.74 |
- |
|
Harrell James Archie Jr |
Exec. VP, Mktg & External Comm |
|
2019-06-10 |
4 |
B |
$2.85 |
$12,523 |
D/D |
4,398 |
8,554 |
2.74 |
- |
|
Miller Joseph M |
Chief Financial Officer |
|
2019-06-07 |
4 |
D |
$4.85 |
$18,057 |
D/D |
(3,723) |
45,054 |
|
- |
|
440 Records found
|
|
Page 6 of 18 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|